<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00560430</url>
  </required_header>
  <id_info>
    <org_study_id>KPUK0106</org_study_id>
    <secondary_id>EudraCT 2006-003567-31</secondary_id>
    <nct_id>NCT00560430</nct_id>
  </id_info>
  <brief_title>Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients</brief_title>
  <acronym>METATEL</acronym>
  <official_title>Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A number of studies have shown that certain blood-pressure medications such as ACE-inhibitors
      and angiotensin-II-receptor blockers (ARB) can reduce the incidence of diabetes mellitus type
      2. This protocol will evaluate whether inflammatory mechanisms mediate this effect. The
      investigators therefore will investigate the effect of telmisartan, a potent ARB, on lipid
      metabolism, glucose metabolism and inflammation in patients with the metabolic syndrome.
      Specific parameters will be tested before treatment and after 3 months of treatment. Placebo
      will be compared to 2 different doses of telmisartan per day.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in IL-6</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in fasting lipids;</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in postprandial lipid metabolism</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in inflammatory parameters</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in glucose metabolism</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Hypertension</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>T1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan 80 mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan 160 mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan</intervention_name>
    <description>80 mg per day, orally, weeks 1-14</description>
    <arm_group_label>T1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan</intervention_name>
    <description>80 mg per day; orally, weeks 1 and 2; 160 mg per day; orally, weeks 3-14</description>
    <arm_group_label>T2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo; orally weeks 1-14</description>
    <arm_group_label>P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Abd. obesity (BMI&gt;25kg/m²) and waist circumference ≥95cm (men),≥80cm (women)

          -  Blood pressure ≥130 mmHg (systolic) and/or ≥85 mmHg (diastolic)

          -  Triglycerides 150-400 mg/dl

          -  Normal stress test

          -  Normal carotid ultrasound

          -  Normal fundoscopy

        Exclusion Criteria:

          -  Diabetes mellitus

          -  Secondary cause for insulin resistance

          -  LDL-cholesterol &gt;190 mg/dl

          -  Atherosclerotic disease

          -  Blood pressure &gt;160 mmHg (systolic) and/or &gt;100 mmHg (diastolic)

          -  Regular alcohol consumption (&gt;30 g/day)

          -  Contraindication against telmisartan

          -  Antihypertensive medications

          -  Lipid lowering therapy

          -  Malignancy

          -  Pregnancy or Lactation

          -  Women without adequate contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus G Parhofer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ludwig-Maximilians - University of Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Cardiovascular Research, University Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med. Dept. 2, University Munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2007</study_first_submitted>
  <study_first_submitted_qc>November 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2007</study_first_posted>
  <last_update_submitted>July 14, 2010</last_update_submitted>
  <last_update_submitted_qc>July 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Klaus Parhofer, Principal investigator</name_title>
    <organization>Ludwig-Maximilians - University of Munich, Med. Dept. 2,</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

